INTRODUCTION

Breast cancer is one of the most common types of cancer worldwide, particularly among women, with incidence and mortality rates of 24.2% and 15%, respectively, despite being targeted by multipronged therapies. Breast cancer is diverse and heterogeneous with respect to the expression of genes, receptors and intracellular signalling proteins, thereby exhibiting a complex disease aetiology and varied response to therapy. Three major growth factor receptors implicated in breast cancer are progesterone receptor (PR), oestrogen receptor (ER) and human epidermal growth factor receptor 2 (Her2/neu). Based on intertumour heterogeneity recognized by molecular characterization, breast


tumours are categorized into hormone receptor positive (HR+) and HER2+ breast cancers. This classification assists in selecting the appropriate therapy and in monitoring the response to treatment. HR+ tumours are further classified into hormone receptor positive/HER2+ and hormone receptor positive/HER2- breast cancers. The latter, hormone receptor positive/HER2- breast cancers, are a heterogeneous and aggressive group that comprises of tumours that are sensitive to endocrine therapy and those that are resistant to endocrine therapy.

The adverse side effects of chemotherapy coupled with the development of drug resistance have prompted the exploration of natural products to combat cancer. Lactoferricin B (LfcinB) is a natural peptide derived from bovine lactoferrin that exhibits anticancer properties. LfcinB was evaluated in vitro for its inhibitory effects on cell lines representing different categories of breast cancer and in vivo for its suppressive effects on tumour xenografts in NOD-SCID mice.
cancers are categorized as follows: luminal A (ER\textsuperscript{high}, Her2\textsuperscript{low}), luminal B (ER\textsuperscript{low}, Her2\textsuperscript{high}), Her2-enriched (Her2\textsuperscript{high}, ER), basal-like or triple-negative (ER\textsuperscript{−}, PR\textsuperscript{−}, Her2\textsuperscript{−}) and claudin-low (ER, Claudin\textsuperscript{low}, E-cadherin\textsuperscript{low}) types, most of which are associated with a poor short-term prognosis.\textsuperscript{7}

Her2-positive breast cancer is characterized by Her2 receptor overexpression and dependence on Her2 pathway for survival. The prognosis of Her2-positive breast cancers improved dramatically following the use of monoclonal antibodies such as trastuzumab and has worse prognosis than luminal A type.\textsuperscript{4} Triple-negative breast cancer (TNBC) is highly aggressive, heterogeneous and the most difficult type of breast cancer to treat, with a 10 year survival rate of 60%-70%. TNBC responds only to chemotherapy due to the absence of hormone receptors.\textsuperscript{5,6} Antibody-drug conjugates, adjuvant and neo-adjuvant therapies have significantly increased patient outcome although toxicity, relapses and drug resistance are also reported.\textsuperscript{3} Chemotherapy is often accompanied by the development of drug resistance facilitated by multiple resistance mechanisms leading to serious side effects. This has prompted research into the development of natural agents that might help overcome these issues. Many studies have focused on anticancer peptides to explore their potential to kill cancer cells, but most were found to be highly toxic.

Bovine lactoferrin is an iron-binding glycoprotein present in cow milk with antimicrobial, anticancer, and immunomodulatory properties.\textsuperscript{7} Administration of lactoferrin in vivo is safe and well-tolerated, and is effective against some cancers.\textsuperscript{8} Lactoferricin B (LfcinB) is a 25-amino acid peptide released from lactoferrin by acid-pepsin hydrolysis. Similar to other cationic antimicrobial peptides, LfcinB exhibits antibacterial and antifungal properties as well as anticancer properties.

Peptide

LfcinB peptide (FKCRRWQWRMKKLGAPSITCVRRAF) was synthesized by Mimotopes Pty Ltd. The peptide was dissolved in incomplete DMEM to a working concentration of 1 mg/ml.

2.3 | Apoptosis assay

The assay was carried out using the Annexin V-FITC early apoptosis detection kit from Cell Signaling Technology, Inc., following the manufacturer’s instructions. The cells were cultured in 6-well plates and treated with various concentrations of LfcinB peptide for 48 h. The cells were detached using PBS containing 10 mM EDTA, stained and analysed using a flow cytometer (BD FACSCalibur; BD Biosciences).

2.4 | Cell invasion assay

Boyden chambers (8 µM pore size) were pre-coated with fibronectin and placed in 24-well companion plates. In the upper chamber, 2 × 10\textsuperscript{4} cells were placed in serum-free medium containing various concentrations of LfcinB peptide. Complete DMEM (600 µl) was placed in the lower chamber. After 12 h of incubation, the cells that had invaded into the fibronectin-coated lower surface of the membrane were fixed with methanol, stained with 1% crystal violet and counted using Nikon Eclipse Ti-S inverted microscope at 200X magnification.

2.5 | Animals

Immunodeficient NOD-SCID-gamma (NSG) mice were bred and maintained in the SPF facility of the Institute of Medical Research (IMR). Female mice (8 weeks old, weighing 18-25 g) were used in the present study. The mice were housed in groups of 5 animals per cage maintained in a barrier facility equipped...
with HEPA-filtered racks. All the experiments were carried out following the guidelines and approval of the Animal Care and Use Committee (ACUC) of Ministry of Health (ACUC/KKM/02 9/2015) (Sept 2015) and Medical Research and Ethics Committee, Ministry of Health Malaysia, as well as the IMU Joint Committee on Research and Ethics of International Medical University (IMU R 142/2014[6/2014]) (June 2014) within the approval period of 2015-2017.

2.6 | Breast cancer xenografts

MDA-MB-231-GFP-luc2 cells (1 × 10⁶ cells in 25 µl of plain DMEM mixed with 25 µl Matrigel (BD Biosciences)) were injected into the fifth left inguinal mammary fat pad of the female NSG mice. When the tumours became palpable, they were measured using callipers to assess tumour volume. When the tumour reached a volume of ~150-200 mm³, an intratumoural injection of 50 µl of LfcinB peptide (4 or 5 mg) or saline was administered for 3 consecutive days. Once the tumours in the control group reached a volume of ~700 mm³ or a diameter of 11 mm, all mice were killed by an overdose of CO₂ gas in a CO₂ chamber (10%-30% volume/min). The tumours were harvested and photographed, and their volume and weight were recorded. A flow chart of the in vivo experimental protocol is depicted in Figure 1.

2.7 | In vivo imaging systems (IVIS)

For live imaging, the mice were anaesthetized by isoflurane (3% induction dose and 1.5%-2% maintenance dose via a precision vaporizer) and injected with 100 µl of diluted XenoLight D-Luciferin-K⁺ salt, a bioluminescent substrate (PerkinElmer, Inc) intraperitoneally (i.p.) at a concentration of 150 mg/kg bodyweight. The mice were placed in the imaging chamber for fluorescent imaging using IVIS® Spectrum (PerkinElmer, Inc) and imaged ventrally.

2.8 | Histological analysis

The harvested tumours were fixed in 10% formalin and embedded in paraffin for histological analysis. The tissue blocks were cut into 4 µm sections using a microtome (RM2255; Leica Biosystems, Inc). Slides were prepared and stained with haematoxylin and eosin (H&E), and images were captured using Nikon Eclipse 80i microscope at 200X and 400X magnifications.

2.9 | Statistical analysis

Data were analysed using a Student’s t test. Tumour growth curves were compared using a one-way analysis of variance (ANOVA) followed by post hoc Tukey’s honest significant difference (HSD). Differences between treatments were considered significant at the P < .5 probability level.

3 | RESULTS

3.1 | Varied sensitivity of different breast cancer cell lines to LfcinB-induced apoptosis

The different breast cancer cell lines exhibited varying degrees of sensitivity to LfcinB-induced apoptosis, with the SKBR3 and MDA-MB-231 cells reaching ~80% cell death at the 100 and 200 µg/ml concentrations (Figure 2). In the MDA-MB-468 cells, LfcinB induced only ~60% cell death and in the MCF7 cells, only ~50% cell death at the 300 µg/ml concentration. The non-tumorigenic breast epithelial cell line, MCF-10A, exhibited only ~10% cell death, even at the 300 µg/ml concentration of LfcinB. Therefore, the SKBR3 and MDA-MB-231 cell lines were found to be highly sensitive to LfcinB, the MDA-MB-468 and MCF7 cells moderately sensitive and the MCF-10A cells non-responsive to LfcinB. The relative sensitivity of the different cell lines to LfcinB following treatment for 48 h is

---

**FIGURE 1** Flow chart depicting in vivo tumour induction and LfcinB treatment in NSG mice.
collectively depicted in Figure 2F for comparison. The survival percentage was calculated from the apoptosis assay and depicted as a line graph in Figure 2G to illustrate the relative survival of the different cell lines. Representative graphs from the flow cytometric analysis of apoptosis in the different cell lines using Annexin-FITC and propidium iodide are depicted in Figure S1.

3.2 Inhibition of the invasion potential of breast cancer cell lines by LfcinB

LfcinB inhibited the invasive potential of the highly invasive cell lines MDA-MB-231 and MDA-MB-468 in the Boyden chamber assay. The MDA-MB-231 cells treated with 200 µg/ml of LfcinB exhibited only 20% cell invasion, whereas the MDA-MB-468 cells exhibited ~50% cell invasion at the same concentration (Figure 3). The MDA-MB-231...
cells were more sensitive to LfcinB than the MDA-MB-468 cells. The numbers of invading MCF7 and SKBR3 cells were non-significant. The normal MCF-10A cells were non-invasive (data not shown).

3.3 Impairment of tumour growth by LfcinB

The tumour growth rate was slower in mice that received intratumoural injections of LfcinB peptide compared to control mice treated with saline (Figure 4A). The difference in size was apparent from day 7 post-injection, and over time, the gap between the treated and control groups (5 mice/group) became wider. By day 16, while tumour size in the control group reached ~1,000 mm³, that of the treatment group remained <500 mm³. Throughout the experimental period, the bodyweight of the mice was found to be stable in all the groups (Figure 4B).

Imaging of live mice using the IVIS® Spectrum revealed that tumour size and density increased over time in the control group, as depicted by an increasingly intense red colour compared to the LfcinB- treated groups that exhibited a decrease in tumour size, as well as in density. The LfcinB-treated mice had smaller tumours with lower density, as indicated by the shift towards blue colour coupled with a decrease in red colour by day 16 (Figure 5).

Excised tumour volume and weight exhibited the same decreasing trend. The control group had a mean tumour volume of 1,272 mm³, whereas the treatment groups had mean volumes of 319 and 291 mm³, respectively (Figure 6A). Similarly, tumour weight decreased from a mean of 0.81 g in the control group to ~0.23 g in the LfcinB-treated groups (Figure 6B). Images of the excised tumours revealed a marked difference between the control and treated groups (Figure 6C).

3.4 Induction of apoptosis in tumours treated with LfcinB

H&E staining of tumour sections from the LfcinB-treated mice revealed an increased number of apoptotic cells compared to the control mice (Figure 7). This indicated that the intratumoural injection of LfcinB induced the apoptosis of the tumour cells, causing the tumours to shrink.

The current findings confirm the inhibitory effects of LfcinB on cancer cell lines in vitro as well as in vivo, and its ability to induce apoptosis and inhibit cancer cell invasion without affecting normal cells. These characteristics are the prerequisite for targeted therapy and indicate that LfcinB may be a valuable candidate for breast cancer treatment.

4 DISCUSSION

The development of peptides as anticancer agents is aimed at increasing the target specificity to cancer cells while decreasing toxicity and undesirable side effects. Anticancer peptides are generally cationic and exert their toxic effects by interacting with the anionic cancer cell membrane. LfcinB is a cationic peptide rich in basic amino acids with a net positive charge of 7.84, and its selective targeting of cancer cells might be attributed to their elevated negative membrane potential. The differential sensitivity of breast cancer cell lines to therapeutic agents has been reported with the antimicrobial peptide Tempoprin-1CEa, while a similar observation with bladder cancer cell lines was made with the peptide Magainin. The MCF7 cell line is luminal A type and the SKBR3 cell line is Her2-positive; the two triple-negative cell lines, MDA-MB-468 and MDA-MB-231, are basal type and Claudin-low type, respectively. Chemotherapeutic drugs targeting Her2 have exhibited a sensitivity ranking in breast cancer cell lines as follows: SKBR3>MCF7>MDA-MB-468>MDA-MB-231. The SKBR3 cells, which lack functional p53, but have functional caspase-3 were the most sensitive to the drugs used in the present study. In contrast, the MCF7 cells which have functional p53, but not functional caspase-3, were relatively resistant. While the MCF7 cells are responsive to hormone therapy and are associated with the most favourable prognosis, they are relatively resistant to other drugs as well as LfcinB.

Smaller peptide derivatives of LfcinB have been synthesized and have exhibited anticancer properties. A study using the core peptide
RAHMAN et al.
of LfcinB found that a net positive charge of +7 facilitated antitumor activity. The modification of the LfcinB peptide to cluster the cationic residues into a single region caused it to be 9.6-fold more cytotoxic to the HL-60 leukaemic cell line. Lactoferrin-derived peptides have been reported to have weak cytotoxicity against MDA-MB-231 cells, while synthetic peptides in dimeric and tetrameric forms designed with the canonical motif RRWQWR of LfcinB are highly cytotoxic to the MDA-MB-468 and MDA-MB-231 breast cancer cell lines. Even MCF7 cells, which are only moderately sensitive to LfcinB, have been found to be highly sensitive to the lactoferricin core peptide, RRWQWR. LfcinB causes no cytotoxicity to several normal cell lines tested, has immunomodulatory and anti-inflammatory properties and does not elicit adverse side effects.

A variety of mechanisms have been proposed to underlie the anticancer effects of lactoferrin, LfcinB and its derivatives. A common mechanism proposed by many is the induction of apoptosis, membrane disruption and cell cycle arrest in cancer cells treated with lactoferrin or its derivatives. Human lactoferrin was found to arrest the cell cycle at the G1 to S transition phase in MDA-MB-231 cells by inhibiting cyclin-dependent kinases. Another study, lactoferrin was reported to induce cell cycle arrest and inhibit the mTOR signalling pathway, thereby inducing stress, but not apoptosis of breast cancer cell lines. Both lactoferrin and LfcinB were found to induce apoptosis by modulating the expression of pro-apoptotic and anti-apoptotic proteins and caspases in different cancer cell lines, as well as in implanted tumours in animal models. The induction of reactive oxygen species (ROS)
was implicated by some studies in the apoptotic pathway induced by LfcinB.\textsuperscript{31,12,40} Mitochondrial death pathways and caspases have been proposed to be involved in apoptosis induced by LfcinB.\textsuperscript{14,31,41} JNK signalling pathway, which is implicated in mitochondria-mediated apoptosis, was induced by LfcinB in oral cancer cells.\textsuperscript{42} Anti-angiogenic properties have also been attributed to LfcinB as evident by its anti-VEGF effect and decreased expression of matrix metalloproteases (MMPs).\textsuperscript{43}

Both lactoferrin and lactoferricin have tumour-suppressing functions. The expression of lactoferrin cDNA effectively reduced tumours derived from breast cancer as well as cervical cancer.\textsuperscript{39-42} In melanoma and colon carcinoma tumours, disruption of cell membrane, lysis and haemorrhagic necrosis was observed.\textsuperscript{44} Administration of LfcinB dendrplexes intravenously suppressed the growth of A431 and B16-F10 tumour xenografts in mice and prevent tumour metastasis.\textsuperscript{47,49} The intratumoural injection of a 9-mer peptide, LTX-302, which is a derivative of LfcinB, caused tumour necrosis and tumour infiltration by inflammatory cells followed by complete regression of tumours in a T lymphocyte–dependent manner in immunocompetent BALB/c mouse tumour model.\textsuperscript{48} LTX-315, an oncolytic peptide derived from LfcinB, was shown to exert an additive effect when used along with chemotherapy as a combination therapy against triple-negative breast cancers in a mouse model.\textsuperscript{50} It was also able to modulate immune response and reprogram the tumour microenvironment, and is being evaluated in clinical trials.\textsuperscript{51}

Our study has shown that LfcinB is effective against different breast cancer cell lines including triple-negative types and is capable of inducing apoptosis, and inhibiting cell invasion. Intratumoral administration of LfcinB caused significant reduction in tumour burden in vivo. Furthermore, it specifically targeted cancer cells without affecting the normal cells. These properties make LfcinB a promising natural product to be safely considered as a candidate for combination therapy against breast cancer. It can help minimize the dose of chemotherapeutic drugs thereby mitigating the side effects and reduce the overall cost of cancer treatment by serving as a cheaper alternative. Further studies are to be undertaken to evaluate this peptide for treatment of human breast cancer.

ACKNOWLEDGEMENTS

This study was funded by the Ministry of Higher Education under Fundamental Research Grant Scheme (FRGS) project FRGS/1/2014/ SKK01/IMU/03/1 awarded to the corresponding author.

The authors wish to thank the Director General of Health Malaysia for his permission to publish this article. The authors wish to acknowledge Dr Saint Nway Aye, Pathologist, International Medical University, for her help with the interpretation of histopathology slides, as well as Ms Nurul Ashikin Mohamed Shahrehan, Mr Md Noor Shuhada and Ms Christine Ricky of the Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, for their technical help and Prof. Anthony Rhodes, International Medical University, for critically reading through the manuscript.

\textbf{FIGURE 7} LfcinB induces apoptosis in excised tumour sections as depicted by histochemical analysis. Representative sections of tumours from mice treated with saline (A, D) or LfcinB 4 mg (B, E) or LfcinB 5 mg (C, F) shown at 200X (A, B, C) or 400X (D, E, F) magnification depicting apoptotic bodies marked by red arrows. Apoptotic cells are shown at higher magnification within E and F. Scale bars at 50 µm for (A, B, C) and at 25 µm for (D, E, F).
CONFLICT OF INTEREST
The authors confirm that there is no conflict of interest.

AUTHOR CONTRIBUTIONS
Rizdwan Rahman: Formal analysis (supporting); Investigation (lead).
Alyssa Danielle Fonseka: Investigation (supporting). Shiang-Chia Sua: Investigation (supporting). Munirah Ahmad: Methodology (supporting); Resources (supporting); Supervision (supporting); Writing-review & editing (supporting).
Ramkumar Rajendran: Methodology (supporting); Resources (supporting); Supervision (supporting); Writing-review & editing (supporting).
Stephen Ambu: Methodology (supporting); Resources (supporting); Supervision (supporting); Writing-review & editing (supporting).
Fabian Davamani: Conceptualization (supporting); Formal analysis (supporting); Methodology (supporting); Project administration (supporting); Resources (equal); Supervision (supporting); Writing-review & editing (supporting).
Alan Soo-Beng Kho: Methodology (supporting); Resources (supporting); Supervision (supporting); Writing-review & editing (supporting).
Ebenerez Chitra: Conceptualization (lead); Formal analysis (lead); Methodology (lead); Project administration (lead); Resources (lead); Supervision (lead); Writing-original draft (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT
All data generated and analysed during this study are included in this article. Further details are available upon request.

ORCID
Ramkumar Rajendran https://orcid.org/0000-0002-3610-8430
Fabian Davamani https://orcid.org/0000-0001-7297-5948
Alan Soo-Beng Kho https://orcid.org/0000-0002-8268-5271
Ebenerez Chitra https://orcid.org/0000-0002-5818-6587

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
2. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10(10):955-960. https://doi.org/10.4161/cbt.10.10.13879
3. Escrivá-de-Romani S, Arumi M, Bellet M, Saura C. HER2-positive breast cancer: Current and new therapeutic strategies. Breast. 2018;39:80-88. https://doi.org/10.1016/j.breast.2018.03.006
4. Ades F, Zarabas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32(25):2794-2803. https://doi.org/10.1200/JCO.2013.54.1870
5. Fayaz S, Demian GA, El-Sherefy M, Elsaa H, Aziz M, Abuzalouf S. Triple negative breast cancer: 10-year survival update of the applied treatment strategy in kuwait. Gulf J Oncolog. 2019
6. Gonçalves H, Guerra MR, Duarte Cintra JR, Fayer VA, Brum IV. Multifunctional capacity and therapeutic potential of lactoferrin. Life Sci. 2018;195:61-64. https://doi.org/10.1016/j.lfs.2018.01.002
7. Moreno-Expósito L, Illescas-Montes R, Melguizo-Rodriguez L, Ruiz C, Ramos-Torrecillas J, de Luna-Bertos E Multifunctional capacity and therapeutic potential of lactoferrin. Life Sci. 2018;195:61-64. https://doi.org/10.1016/j.lfs.2018.01.002
8. Cutone A, Rosa L, Ianiro G, et al. Lactoferrin's anti-cancer properties: Safety, selectivity, and wide range of action. Biomolecules. 2020;10(3):456-https://doi.org/10.3390/biom10030456
9. Fernandes KE, Carter DA. The antifungal activity of lactoferrin and its derived peptides: Mechanisms of action and synergy with drugs against fungal pathogens. Front Microbiol. 2017;8: https://doi.org/10.3389/fmicb.2017.00002
10. Sinha M, Kaushik S, Kaur P, Sharma S, Singh TP. Antimicrobial lactoferrin peptides: The hidden players in the protective function of a multifunctional protein. Int J Pept. 2013;2013:1-12. https://doi.org/10.1155/2013/390230
11. Hilchie AL, Vale R, Zemlak TS, Hoskin DW. Generation of a hematologic malignancy-selective membrane-restricted peptide from the antimicrobial core (RRWQWR) of bovine lactoferrin. Exp Mol Pathol. 2013;95(2):192-198. https://doi.org/10.1016/j.yexmp.2013.07.006
12. Yoo YC, Watanabe R, Kojii Y, et al. Apoptosis in human leukemic cells induced by lactoferrin, a bovine milk protein-derived peptide: Involvement of reactive oxygen species. Biochem Biophys Res Commun. 1997; https://doi.org/10.1006/bbrc.1997.7199
13. Pan WR, Chen PW, Chen YLS, Hsu HC, Lin CC, Chen WJ. Bovine lactoferrin B induces apoptosis of human gastric cancer cell line AGS by inhibition of autophagy at a late stage. J Dairy Sci. 2013;96(12):751-752. https://doi.org/10.3168/jds.2013.7285
14. Eissensen LT, Berge G, Leknessund A, et al. The antimicrobial peptide, Lactoferrin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer. 2006;119(3):493-500. https://doi.org/10.1002/ijc.21886
15. Furlong SJ, Mader JS, Hoskin DW. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts. Exp Mol Pathol. 2010;88(3):371-375. https://doi.org/10.1016/j.yexmp.2010.02.001
16. Furlong SJ, Mader JS, Hoskin DW. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep. 2006;15(5):1385-1390. https://doi.org/10.3892/or.15.5.1385
17. Richardson A, de Antueroo R, Duncan R, Hoskin DW Intracellular delivery of bovine lactoferricin’s antimicrobial core (RRWQWR) kills T-leukemia cells. Biochem Biophys Res Commun. 2009;388(4):731-741. https://doi.org/10.1016/j.bbrc.2009.08.083
18. Arias M, Hilchie AL, Haney EF, et al. Anticancer activities of bovine and human lactoferricin-derived peptides1. Biochem Cell Biol. 2017;95(1):91-98. https://doi.org/10.1139/bcb-2016-0175
19. Lehmann J, Retz M, Siddhu SS, et al. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol. 2006;50(1):141-147. https://doi.org/10.1016/j.eururo.2005.12.043
20. Dobrzynska I, Szachowicz-Petelska B, Sulkowski S, Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol Cell Biochem. 2005;276(1-2):113-119. https://doi.org/10.1007/s11010-005-3557-3
21. Vogel HJ, Schibli DJ, Jing W, Lohmeier-Vogel EM, Epand RF, Epand RM. Towards a structure-function analysis of bovine lactoferrin and related tryptophan- and arginine-containing peptides. Biochem Cell Biol. 2002;80(1):49-63. https://doi.org/10.1139/bcb-2002-0170
22. Wang C, Tian L-L, Li S, et al. Rapid cytotoxicity of antimicrobial peptide tempoprin-Icea in breast cancer cells through membrane destruction and intracellular calcium mechanism. PLoS One. 2013;8(4):e60462-https://doi.org/10.1371/journal.pone.0060462
23. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4): https://doi.org/10.1186/bcr2889
24. Chavez KJ, Garmella SV, Lipkowitz S. Triple negative breast cancer cell lines: One tool in the search for better treatment of triple
negative breast cancer. Breast Dis. 2011;32(1-2):35-48. https://doi.org/10.3233/BD-2010-0307

Stanley A, Ashrafi GH, Seddon AM, Modjtabehdi H. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep. 2017;7(1): https://doi.org/10.1038/s41598-017-04301-8

Friedrich K, Wieder T, Von Haefen C, et al. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene. 2001;20(22):2749-2760. https://doi.org/10.1038/sj.onc.1204342

Perchellet EM, Crow KR, Gakhar G, et al. Bioactivity and molecular targets of novel substituted quinolines in murine and human tumor cell lines in vitro. Int J Oncol. 2010; https://doi.org/10.3892/ijo.00000543

Solarte VA, Rosas JE, Rivera ZJ, Arango-Rodríguez ML, García JE, Vélez E. Antibacterial synthetic peptides derived from bovine lactoferricin exhibit specific cytotoxic effects against oral squamous-cell carcinoma cell lines. Biomed Res Int. 2015;2015:1-13. https://doi.org/10.1155/2015/630179

Onishi J, Roy MK, Juneca LR, Watanabe Y, Tamai Y. A tetrameric peptide derived from bovine lactoferricin exhibits specific cytotoxic effects against oral squamous-cell carcinoma cell lines. Biomed Res Int. 2015; https://doi.org/10.1155/2015/630179

28. Vargas Casanova Y, Rodríguez Guerra JA, Umaña Pérez YA, et al. The tetrameric peptide LfcinB (20–25)4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line. Molecules. 2017;22(10):1641-https://doi.org/10.3390/molecules22101641

29. Guerra JR, Cárdenas AB, Ochoa-Zarzosa A, et al. The tetrameric peptide LfcinB (20–25)4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line. RSC Adv. 2019; https://doi.org/10.1039/c9ra04145a

30. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 2005;4(4):612-624. https://doi.org/10.1158/1535-7163.MCT-04-0077

31. Legrand D, Ellass E, Carpentier M, Mazurier J. Lactoferrin: A modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005;62(22): https://doi.org/10.1007/s00018-005-5370-2

32. Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-Figueroa BF, García-Montoya IA, Salazar-Martinez J, Rascón-Cruz Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin. 2014;35(5):557-566. https://doi.org/10.1038/aps.2013.200

33. Zhang Y, Lima CF, Rodrigues LR. Anticancer effects of lactoferrin: Underlying mechanisms and future trends in cancer therapy. Nutr Rev. 2014;72(12):763-773. https://doi.org/10.1111/nure.12155

34. Damens E, El Yazidi I, Mazurier J, Duthille I, Spiik G, Boilly-Marer Y. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem. 1999; https://doi.org/10.1002/(SICI)1097-4644(19990901)74:3<486:AID-JCB16>3.0.CO;2-6

35. Zhanger Y, Nicolaou A, Lima CF, Rodriguez LR. Bovine lactoferrin induces cell cycle arrest and inhibits mtor signaling in breast cancer cells. Nutr Cancer. 2014;66(8):1371-1385. https://doi.org/10.1080/01635581.2014.956260

36. Sheng M, Zhao Y, Zhang A, Wang L, Zhang G. The effect of LfcinB9 on human ovarian cancer cell SK-OV-3 is mediated by inducing apoptosis. J Pept Sci. 2014;20(10):803-810. https://doi.org/10.1002/jpsc.2670

37. Sakai T, Banno Y, Kato Y, Nozawa Y, Kawaguchi M. Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J Pharmacol Sci. 2005;98(1):41-48. https://doi.org/10.1254/jphs.FPJ04047X

38. Yan D, Chen D, Shen J, Xiao G, van Wijnen AJ, Im H-J. Bovine lactoferricin is anti-inflammatory and anti-catabolic in human articular cartilage and synovium. J Cell Physiol. 2013;228(2):447-456 https://doi.org/10.1002/jcp.24151

39. Wang J, Li Q, Li K, et al. Effects of adenosine vectors mediated human lactoferrin cDNA on mice bearing EMT6 breast carcinoma. Pharmazie. 2011; https://doi.org/10.1691/ph.2011.1534

40. Li WY, Li QW, Han ZS, et al. Growth suppression effects of recombinant adenosine expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011; https://doi.org/10.1089/cbr.2010.0937

41. Wang J, Li Q, Ou Y, et al. Inhibition of tumor growth by recombinant adenosine containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res. 2011;34(6):987-995. https://doi.org/10.1007/s12272-011-0616-z

42. Tone Eliassen L, Berge G, Sveinbjørnsnnson B, Svendsen JS, Vorland LH, Rekdal Ø. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 2002;22(5):2703-2710.

43. Lim LY, Koh PY, Somani S, et al. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomedicine Nanotechnology, Biol Med. 2015;11(6):1445-1454. https://doi.org/10.1016/j.nano.2015.04.006

44. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki KI, Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Japanese J Cancer Res. 1997;88(2):184-190. https://doi.org/10.1111/j.1349-7006.1997.tb00364.x

45. BERGE G, ELIASSEN LT, CAMILIO KA, BARTNES K, SVEINBJØRNSNÖ, B, REKDAL Ø. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother. 2010;59(8):1285-1294. https://doi.org/10.1007/s00262-010-0857-6

46. Camilio KA, Wang M-Y, Mauseth B, et al. Combining the oncolytic peptide LTX-315 with doxorubin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Res. 2019;21(1): https://doi.org/10.1186/s13058-018-1092-x

47. Sveinbjørnsnö B, Camilio KA, Haug BE, Rekdal Ø. LTX-315: A first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Med Chem. 2017;9(12):1339-https://doi.org/10.4155/fmc-2017-0088

48. Mader JS, Richardon A, Salsman J, et al. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res. 2007;313(12):2634-2650. https://doi.org/10.1016/j.yexcr.2007.05.015

49. Lee SH, Hwang HM, Pyo CW, Hahn DH, Choi SY. E2F1-directed activation of Bcl-2 is correlated with lactoferrin-induced apoptosis in Jurkat leukemia T lymphocytes. Biometals. 2010;23(3):507-514. https://doi.org/10.1007/s10534-010-9341-1

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.